Mar 18, 2019 / 09:00PM GMT
Operator
Greetings, and welcome to Amarin's discussion on Transforming the Unprecedented REDUCE-IT Study Results into Clinical Practice. (Operator Instructions) It is now my pleasure to introduce Elisabeth Schwartz, Senior Director of Investor Relations for Amarin. Please go ahead, Elisabeth.
Elisabeth Schwartz - Amarin Corporation plc - Senior Director of IR
Thank you. Welcome to today's discussion on Transforming the Unprecedented REDUCE-IT Study Results into Clinical Practice. The slides accompanying this call are on our Investors section of www.amarincorp.com. If interested in (inaudible), please reference the forward-looking statements section in the reference slide on Amarin's website.
I would like to turn the call over to Dr. Craig Granowitz, the Chief Medical Officer of Amarin.
Craig B. Granowitz - Amarin Corporation plc - Chief Medical Officer & Senior VP
Thank you, Elisabeth, and thank you all to our panelists and the listeners who called
Amarin Corporation plc - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot